The Quantellect read.As of Nov 19, 2026, 16 active firms cover Rhythm Pharmaceuticals Inc: 15 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $120.00 to $160.00, so the covering firms are broadly aligned. The average target of $143.64 sits 21% above the current $119.15. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.69 next quarter toward $-1.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 active firms
Buy
Strong Buy00%
Buy1594%
Neutral16%
Sell00%
Strong Sell00%
Based on 16 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$143.64
+20.6% upside
Average target across 14 active firms as of Nov 19, 2026 vs $119.15 current
Highest Target$160.00
Average Target$143.64
Lowest Target$120.00
Detailed analyst forecasts for RYTM
Showing 1–14 of 14 named analysts shown · 16 active firms in the rating projection
As of Nov 19, 2026, 15 of 16 active firms rate RYTM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RYTM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.69
Range $-0.91 – $-0.45 · 4 analysts · -17% YoY
Next period, 4 analysts expect Rhythm Pharmaceuticals Inc to earn $-0.69 a share (range $-0.91 – $-0.45), versus $-0.83 a year earlier. Full-year consensus is $-4.94, growing to $-1.30 the year after.
REVENUE · NEXT QUARTER
$112.1M
Range $93.6M – $120.0M · 4 analysts · +87% YoY
Revenue is expected to reach $112.1M (range $93.6M – $120.0M), +86.6% year-over-year. Full-year consensus is $330.6M, rising to $578.2M next year.
Top analysts covering Rhythm Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RYTM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$136.00+14.1% to target
Overall win rate
64%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$166.00+39.3% to target
Overall win rate
43%
+ Follow
#3
Joseph Stringer
Needham · Rank #256
Buy
$130.00+9.1% to target
Overall win rate
36%
+ Follow
#4
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$143.00+20.0% to target
Overall win rate
41%
+ Follow
#5
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$154.00+29.2% to target
Overall win rate
35%
+ Follow
RYTM stock forecast FAQ
What is RYTM's average 12-month price target?+
The 14 active firms with a live target average $143.64 for Rhythm Pharmaceuticals Inc over the next 12 months, ranging from a $160.00 high to a $120.00 low, as of Nov 19, 2026.
Is RYTM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 16 active firms as of Nov 19, 2026, 15 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RYTM?+
The Street-high target is $160.00 (Citizens), and the Street-low is $120.00 (Deutsche Bank). The average of all 14 active-firm targets is $143.64.
How many active Wall Street firms cover RYTM?+
16 active firms have a recognized rating on Rhythm Pharmaceuticals Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RYTM?+
Among analysts who currently cover RYTM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $136.00 target.
What is Rhythm Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.69 per share (range $-0.91 – $-0.45) across 4 analysts. Full-year EPS is projected at $-4.94, rising to $-1.30 the following year.
How much revenue is Rhythm Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $112.1M (range $93.6M – $120.0M). Full-year revenue is projected at $330.6M, growing to $578.2M next year.
Have analysts been upgrading or downgrading RYTM lately?+
As of Nov 19, 2026, 15 of 16 active firms rate RYTM a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RYTM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.